Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial

1. Pozniak, A.
2. Markowitz, M.
3. Mills, A.
4. Stellbrink, H.-J.
5. Antela, A.
6. Domingo, P.
7. Girard, P.-M.
8. Henry, K.
9. Nguyen, T.
10. Piontkowsky, D.
11. Garner, W.
12. White, K.
13. Guyer, B.